JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 102 filers reported holding JOUNCE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $48,285 | +66.7% | 26,100 | 0.0% | 0.00% | – |
| Q4 2022 | $28,971 | -100.0% | 26,100 | -64.1% | 0.00% | -100.0% |
| Q3 2022 | $85,085,000 | +106256.2% | 72,700 | +177.0% | 0.00% | 0.0% |
| Q2 2022 | $80,000 | -53.8% | 26,250 | +3.1% | 0.00% | -50.0% |
| Q1 2022 | $173,000 | -18.8% | 25,450 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $213,000 | +12.7% | 25,450 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $189,000 | +9.2% | 25,450 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $173,000 | -33.7% | 25,450 | -0.0% | 0.00% | -33.3% |
| Q1 2021 | $261,000 | +9.7% | 25,451 | -28.7% | 0.00% | 0.0% |
| Q4 2020 | $238,000 | -99.9% | 35,700 | +40.3% | 0.00% | -25.0% |
| Q3 2020 | $208,000,000 | – | 25,450 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 2,697,829 | $22,527,000 | 93.16% |
| TRV GP III, LLC | 1,148,780 | $9,592,000 | 2.40% |
| Deep Track Capital, LP | 4,000,000 | $33,400,000 | 2.36% |
| Ally Bridge Group (NY) LLC | 575,000 | $4,801,000 | 1.68% |
| Logos Global Management LP | 1,350,000 | $11,273,000 | 1.16% |
| PFM Health Sciences, LP | 3,972,868 | $33,173,000 | 1.13% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 245,829 | $2,053,000 | 0.83% |
| Yorktown Management & Research Co Inc | 137,300 | $1,146,000 | 0.77% |
| Sofinnova Investments, Inc. | 1,582,777 | $13,216,000 | 0.77% |
| ACUTA CAPITAL PARTNERS, LLC | 127,500 | $1,065,000 | 0.45% |